**Core Concept**
The question is testing knowledge of pharmacological interventions in myocardial infarction (MI), specifically the use of a drug that reduces mortality and morbidity in this condition. The underlying principle is the ability to identify and apply an evidence-based treatment for acute coronary syndrome.

**Why the Correct Answer is Right**
The correct answer is **A. Thrombolytic therapy**. Thrombolytic agents, such as alteplase (tPA), are used to dissolve occluding thrombi in coronary arteries, restoring blood flow to the ischemic myocardium. This is crucial in reducing infarct size and improving outcomes in patients with ST-elevation myocardial infarction (STEMI). Thrombolytic therapy works by activating plasminogen to plasmin, which then degrades fibrin clots.

**Why Each Wrong Option is Incorrect**
**Option B:** **Antiplatelet therapy** is important in the management of acute coronary syndrome but is not the primary treatment for MI. It is used to prevent further thrombus formation but does not dissolve existing clots.
**Option C:** **Beta blockers** are used in the management of MI to reduce myocardial oxygen demand and prevent further cardiac remodeling. However, they do not directly dissolve occluding thrombi.
**Option D:** **Angiotensin-converting enzyme inhibitors** (ACE inhibitors) are used in the long-term management of MI to reduce cardiac remodeling and improve survival. They are not used to treat acute occlusion in MI.

**Clinical Pearl / High-Yield Fact**
It's essential to remember that thrombolytic therapy should be administered within 3-4 hours of MI onset and is most effective in patients with STEMI. It's also crucial to note that the use of thrombolytic therapy may increase the risk of bleeding complications.

**Correct Answer:** A. Thrombolytic therapy.